Pharmacophore modeling and applications in drug discovery: Challenges and recent advances

Drug Discovery Today

Volumn 15, Issue 11-12, 2010, Pages 444-450

  Yang, Sheng Yong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2 INHIBITOR; LIGAND;

DRUG DEVELOPMENT; DRUG RESEARCH; MOLECULAR MODEL; PHARMACOPHORE; REVIEW;

DRUG DESIGN; DRUG DISCOVERY; HUMANS; LIGANDS; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING;

EID: 77954818699     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2010.03.013     Document Type: Review

References (59)

1. Ehrlich P. Ueber den jetzigen Stand der Chemotherapie. Ber. Dtsch. Chem. Ges. 1909, 42:17-47.
2. Wermuth C.G., et al. Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1997). Annu. Rep. Med. Chem. 1998, 33:385-395.
3. Günd P. Evolution of the pharmacophore concept in pharmaceutical research. Pharmacophore Perception, Development, and Use in Drug Design 2000, 171-189. International University Line (IUL). O.F. Güner (Ed.).
4. Wermuth C.G. Pharmacophores: historical perspective and viewpoint from a medicinal chemist. Pharmacophores and Pharmacophore Searches 2006, 3-13. Wiley-VCH. T. Langer, R.D. Hoffmann (Eds.).
5. Dror O., et al. Predicting molecular interactions in silico. I. An updated guide to pharmacophore identification and its applications to drug design. Front. Med. Chem. 2006, 3:551-584.
6. Kubinyi H. Success stories of computer-aided design. Computer Applications in Pharmaceutical Research and Development 2006, 377-424. Wiley-Interscience. S. Ekins (Ed.).
7. Mustata G., et al. Discovery of novel Myc-Max heterodimer disruptors with a three-dimensional pharmacophore model. J. Med. Chem. 2009, 52:1247-1250.
8. Barnum D., et al. Identification of common functional configurations among molecules. J. Chem. Inf. Comput. Sci. 1996, 36:563-571.
9. Li H., et al. HypoGen: an automated system for generating 3D predictive pharmacophore models. Pharmacophore Perception, Development, and Use in Drug Design 2000, 171-189. International University Line. O.F. Güner (Ed.).
10. Martin Y.C. DISCO: what we did right and what we missed. Pharmacophore Perception, Development, and Use in Drug Design 2000, 49-68. International University Line. O.F. Güner (Ed.).
11. Jones G., Willet P. GASP: genetic algorithm superimposition program. Pharmacophore Perception, Development, and Use in Drug Design 2000, 85-106. International University Line. O.F. Güner (Ed.).
12. Dixon S.L., et al. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening. 1. Methodology and preliminary results. J. Comput. Aid. Mol. Des. 2006, 20:647-671.
13. Poptodorov K., et al. Pharmacophore model generation software tools. Pharmacophores and Pharmacophore Searches 2006, 17-47. Wiley-VCH. T. Langer, R.D. Hoffmann (Eds.).
14. Van Drie J.H. Pharmacophore discovery: a critical review. Computational Medicinal Chemistry for Drug Discovery 2004, 437-460. Marcel Dekker. P. Bultinck (Ed.).
15. Wolber G., et al. Molecule-pharmacophore superpositioning and pattern matching in computational drug design. Drug Discov. Today 2008, 13:23-29.
16. Smellie A., et al. Poling: promoting conformational variation. J. Comput. Chem. 1994, 16:171-187.
17. Gippert G.P., et al. Distributed torsion angle grid search in high dimensions: a systematic approach to NMR structure determination. J. Biomol. NMR 1998, 11:241-263.
18. Hurst T. Flexible 3D searching: the directed tweak technique. J. Chem. Inf. Comput. Sci. 1994, 34:190-196.
19. Jones G., et al. A genetic algorithm for flexible molecular overlay and pharmacophore elucidation. J. Comput. Aid. Mol. Des. 1995, 9:532-549.
20. Li Z., Scheraga H.A. Monte Carlo-minimization approach to the multiple-minima problem in protein folding. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:6611-6615.
21. Sperandio O., et al. MED-3DMC: a new tool to generate 3D conformation ensembles of small molecules with a Monte Carlo sampling of the conformational space. Eur. J. Med. Chem. 2009, 44:1405-1409.
22. Liu X., et al. Cyndi: a multi-objective evolution algorithm based method for bioactive molecular conformational generation. BMC Bioinformatics 2009, 10:1-14.
23. Li J., et al. CAESAR: a new conformer generation algorithm based on recursive buildup and local rotational symmetry consideration. J. Chem. Inf. Model. 2007, 47:1923-1932.
24. Bandyopadhyay D., Agrafiotis D.K. A self-organizing algorithm for molecular alignment and pharmacophore development. J. Comput. Chem. 2008, 29:965-982.
25. Totrov M. Atomic property fields: generalized 3D pharmacophoric potential for automated ligand superposition, pharmacophore elucidation and 3D QSAR. Chem. Biol. Drug Des. 2008, 71:15-27.
26. Nettles J.H., et al. Flexible 3D pharmacophores as descriptors of dynamic biological space. J. Mol. Graph. Model. 2007, 26:622-633.
27. Baroni M., et al. A common reference framework for analyzing/comparing proteins and ligands. Fingerprints for Ligands and Proteins (FLAP): theory and application. J. Chem. Inf. Model. 2007, 47:279-294.
28. Hecker E.A., et al. Use of Catalyst pharmacophore models for screening of large combinatorial libraries. J. Chem. Inf. Comput. Sci. 2002, 42:1204-1211.
29. Toba S., et al. Using pharmacophore models to gain insight into structural binding and virtual screening: an application study with CDK2 and human DHFR. J. Chem. Inf. Model. 2006, 46:728-735.
30. Vadivelan S., et al. Virtual screening studies to design potent CDK2-Cyclin A inhibitors. J. Chem. Inf. Model. 2007, 47:1526-1535.
31. Wolber G., et al. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J. Chem. Inf. Model. 2005, 45:160-169.
32. Chen J., Lai L.H. Pocket v.2: further developments on receptor-based pharmacophore modeling. J. Chem. Inf. Model. 2006, 46:2684-2691.
33. Ortuso F., et al. GBPM: GRID based pharmacophore model. Concept and application studies to protein-protein recognition. Bioinformatics 2006, 22:1449-1455.
34. Böhm H.J. The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J. Comput. Aid. Mol. Des. 1992, 6:61-78.
35. Barillari C., et al. Hot-spots-guided receptor-based pharmacophores (HS-Pharm): a knowledge-based approach to identify ligand-anchoring atoms in protein cavities and prioritize structure-based pharmacophores. J. Chem. Inf. Model. 2008, 48:1396-1410.
36. Tintori C. Targets looking for drugs: a multistep computational protocol for the development of structure-based pharmacophores and their applications for hit discovery. J. Chem. Inf. Model. 2008, 48:2166-2179.
37. Goodford P.J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 1985, 28:849-857.
38. Zou J., et al. Towards more accurate pharmacophore modeling: multicomplex-based comprehensive pharmacophore map and most-frequent-feature pharmacophore model of CDK2. J. Mol. Graph. Model. 2008, 27:430-438.
39. Zhao H. Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective. Drug Discov. Today 2007, 12:149-155.
40. Ullmann J.R. An algorithm for subgraph isomorphism. J. ACM 1976, 23:31-42.
41. Barnard J.M. Substructure searching methods: old and new. J. Chem. Inf. Comput. Sci. 1993, 33:532-538.
42. Xu J. GMA: a generic match algorithm for structural homorphism, isomorphism, maximal common substructure match and its applications. J. Chem. Inf. Comput. Sci. 1996, 36:25-34.
43. Triballeau N., et al. Are you sure you have a good model? Pharmacophores: historical perspective and viewpoint from a medicinal chemist. Pharmacophores and Pharmacophore Searches 2006, 325-364. Wiley-VCH. T. Langer, R.D. Hoffmann (Eds.).
44. Sun H. Pharmacophore-based virtual screening. Curr. Med. Chem. 2008, 15:1018-1024.
45. Deng J., et al. Dynamic pharmacophore model optimization: identification of novel HIV-1 integrase inhibitors. J. Med. Chem. 2006, 49:1684-1692.
46. Giménez-Oya V., et al. Mimicking direct protein-protein and solvent-mediated interactions in the CDP-methylerythritol kinase homodimer: a pharmacophore-directed virtual screening approach. J. Mol. Model. 2009, 15:997-1007.
47. Talevi A., et al. Combined virtual screening strategies. Curr. Comput. Aid. Drug. Des. 2009, 5:23-37.
48. Kirchmair J., et al. Enhancing drug discovery through in silico screening: strategies to increase true positives retrieval rates. Curr. Med. Chem. 2008, 15:2040-2053.
49. Muegge I. Synergies of virtual screening approaches. Mini Rev. Med. Chem. 2008, 8:927-933.
50. Deng X.-Q., et al. Pharmacophore modeling and docking study for identification of new Aurora-A kinase inhibitors. Chem. Biol. Drug Des. 2008, 71:533-539.
51. Xie H.-Z., et al. Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors. Bioorg. Med. Chem. Lett. 2009, 19:1944-1949.
52. Ren J.-X., et al. Pharmacophore modeling and virtual screening for the discovery of new transforming growth factor-β type I receptor (ALK5) inhibitors. Eur. J. Med. Chem. 2009, 11:4259-4265.
53. Tschinke V., Cohen N. The NEWLEAD program: a new method for the design of candidate structures from pharmacophoric hypotheses. J. Med. Chem. 1993, 36:3863-3870.
54. Roe D.C., Kuntz I. BUILDER v.2: improving the chemistry of a de novo design strategy. J. Comput. Aid. Mol. Des. 1995, 9:269-282.
55. Huang Q., et al. PhDD: a new pharmacophore-based de novo design method of drug-like molecules combined with assessment of synthetic accessibility. J. Mol. Graph. Model. 2010, 10.1016/j.jmgm.2010.02.002.
56. Brenk R., Klebe G. 'Hot spot' analysis of protein-binding sites as a prerequisite for structure-based virtual screening and lead optimization. Pharmacophores and Pharmacophore Searches 2006, 171-192. Wiley-VCH. T. Langer, R.D. Hoffmann (Eds.).
57. Wei D., et al. Discovery of multi-target inhibitors by combining molecular docking with common pharmacophore matching. J. Med. Chem. 2008, 51:7882-7888.
58. Steindl T.M., et al. Parallel screening: a novel concept in pharmacophore modeling and virtual screening. J. Chem. Inf. Model. 2006, 46:2146-2157.
59. Rollinger J.M., et al. Acetylcholinesterase inhibitory activity of scopolin and scopoletin discovered by virtual screening of natural products. J. Med. Chem. 2004, 47:6248-6254.